rurioctocog alfa pegol: clinical use

Prescribing considerations

• Initiate and supervise treatment through clinicians experienced in haemophilia care.
• Safety and efficacy have not been established in previously untreated patients.
• Consider existing cardiovascular risk factors and complications associated with central venous access devices.
• Account for sodium exposure in patients following a controlled-sodium diet.
• Record the product name and batch number for every administration.

Contraindications and cautions

• Hypersensitivity to rurioctocog alfa pegol, octocog alfa or any excipient
• Known allergy to mouse or hamster proteins

Monitoring

• Assess clinical haemostatic response and plasma factor VIII activity; precise coagulation monitoring is particularly important during major surgery.
• Test for factor VIII inhibitors if expected activity is not achieved or bleeding remains uncontrolled.
• Either a chromogenic substrate assay or a routinely used one-stage clotting assay may be used for factor VIII monitoring.

Clinical pharmacology

A recombinant human factor VIII molecule derived from octocog alfa and covalently linked to polyethylene glycol. It restores factor VIII activity temporarily, while PEGylation reduces clearance and extends plasma half-life.

Formulation and product differences

• Supplied as powder with water for injections and reconstituted before intravenous administration.
• Presentations may use a separate BAXJECT II Hi-Flow reconstitution device or a preassembled BAXJECT III system.
• The selected presentation uses a 5 mL solvent and is marked discontinued on eMC.
• The reconstituted solution must not be mixed with other medicines and should not be used if cloudy, discoloured or particulate.